KAICO is a biotechnology company that provides hard-expressing proteins to develop drugs with a silkworm-baculovirus expression system.
KAICO has raised $3.8M in total funding. The most recent round was Series B. The last funding was announced in April 2025.
KAICO's investors include Mizuho Capital, FFG Venture Business Partners, ITOCHU Technology Ventures, JMTC Capital, Higin Capital.
KAICO is headquartered in Nishiku, Japan.
KAICO is a biotechnology company that provides hard-expressing proteins to develop drugs with a silkworm-baculovirus expression system.
KAICO is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"KAICO — Funding & Investors." VCBacked, April 15, 2025, https://www.vcbacked.co/company/kaico. Accessed July 20, 2026.
VCBacked. (2025). KAICO — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/kaico
{{cite web |title=KAICO — Funding & Investors |url=https://www.vcbacked.co/company/kaico |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated